Penumbra, Inc. Reports Third Quarter 2026 Financial Results

Penumbra posts strong Q3 growth but halts guidance amid Boston Scientific acquisition.

What the company is saying

Penumbra, Inc. reports third quarter 2026 revenue of $410.1 million, up 15.6% year-over-year, highlighting robust growth in its thrombectomy business with global thrombectomy revenue at $279.2 million, an 18.1% increase. The company emphasizes strong U.S. VTE revenue growth of 26.0% and U.S. neuro revenue growth of 19.3%. Gross profit margin improved to 68.3%, up 0.5% from the prior year, while total operating expenses reached $229.6 million, including $7.1 million in acquisition-related costs tied to the pending Boston Scientific transaction. Penumbra frames its narrative around operational momentum but explicitly states it will not provide full-year 2026 guidance or host a conference call due to the acquisition process. The tone is factual and measured, focusing on realised performance and the impact of the acquisition on disclosure practices. No executive quotes or forward-looking operational claims are included beyond procedural statements about the acquisition.

What the data suggests

The disclosed figures show Penumbra is delivering double-digit revenue growth across all major segments, with Q3 2026 revenue of $410.1 million and net income of $42.3 million. Thrombectomy remains the primary driver, contributing $279.2 million globally, while embolization and access added $131.0 million. Gross profit margin at 68.3% reflects operational efficiency, and net income per share was $1.07, both basic and diluted. U.S. revenue accounted for $324.2 million, while international revenue was $85.9 million. Operating expenses totaled $229.6 million, with $25.4 million in R&D and $204.2 million in SG&A, the latter including $7.1 million in acquisition-related costs. The balance sheet is strong, with $254.3 million in cash and $419.3 million in marketable investments as of September 30, 2026. The company is not providing forward guidance, which limits visibility into future quarters, but current results indicate sustained profitability and growth. The absence of a conference call or guidance is directly attributed to the pending Boston Scientific acquisition, not operational uncertainty.

Analysis

The announcement is a factual quarterly financial disclosure, providing detailed realised results for Q3 2026, including revenue, gross profit, operating expenses, net income, and segment breakdowns. All key claims are supported by specific numerical data, and the only forward-looking statement is procedural (the absence of future guidance due to the pending acquisition). There is no promotional or exaggerated language; the tone is neutral and focused on reporting actual performance. The benefits of the reported growth are immediate, as evidenced by the strong year-over-year increases in revenue and profitability. Acquisition-related expenses are disclosed transparently, and there is no indication of a large capital outlay with only long-dated or uncertain returns. The gap between narrative and evidence is negligible, as all claims are substantiated by hard data.

Risk flags

• ●The pending acquisition by Boston Scientific introduces uncertainty regarding the timing and likelihood of deal completion, as regulatory approvals are still required and the process could be delayed or terminated.
• ●Penumbra will not provide financial guidance for the remainder of 2026 or host a conference call, reducing transparency and limiting investor insight into near-term operational trends or management’s outlook.
• ●Acquisition-related expenses of $7.1 million impacted Q3 operating expenses, and further costs or integration challenges could affect future profitability if the deal proceeds.
• ●Operational momentum is strong, but the company’s standalone trajectory is now subordinate to the acquisition outcome, which may alter strategic priorities or disrupt ongoing initiatives.

Bottom line

Penumbra’s Q3 2026 results show robust revenue and profit growth, with all key operating metrics moving in a positive direction. The company is executing well in its core thrombectomy and neuro segments, and maintains a strong balance sheet with over $254 million in cash and $419 million in marketable investments. However, the pending acquisition by Boston Scientific overshadows forward visibility, as Penumbra has suspended guidance and will not hold a conference call. Investors face heightened uncertainty around deal closure and future integration, with regulatory approval still pending and additional acquisition-related costs possible. The most important takeaway is that Penumbra’s current financial performance is strong, but the investment thesis now depends on the outcome and terms of the Boston Scientific transaction rather than ongoing standalone operations.

Announcement summary

(NYSE:PEN) Penumbra, Inc. reported revenue of $410.1 million for the third quarter ended September 30, 2026, representing a 15.6% increase compared to the third quarter of 2025. Global thrombectomy revenue was $279.2 million in Q3 2026, up 18.1% year-over-year. U.S. VTE revenue increased 26.0% compared to the same period a year ago. Global embolization and access revenue reached $131.0 million in Q3 2026, an increase of 10.8% from Q3 2025. U.S. neuro revenue was $77.9 million in Q3 2026, up 19.3% year-over-year. Gross profit margin for Q3 2026 was 68.3%, an increase of 0.5% compared to Q3 2025. Total operating expenses for Q3 2026 were $229.6 million, including R&D expenses of $25.4 million and SG&A expenses of $204.2 million, which includes $7.1 million of acquisition-related expenses associated with the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE:BSX). Income from operations was $50.7 million and net income was $42.3 million for Q3 2026. As a result of the pending acquisition by Boston Scientific Corporation, Penumbra will not provide financial guidance for the full year 2026 or host a conference call for Q3 2026 results. As of September 30, 2026, cash and cash equivalents were $254,282,000, and marketable investments were $419,330,000. Accounts receivable, net, were $195,216,000, and inventories were $459,132,000. Total current assets were $1,376,631,000, and total assets were $2,025,103,000. Accounts payable as of September 30, 2026, were $41,961,000, and total current liabilities were $233,810,000. Total liabilities were $441,594,000, and total stockholders' equity was $1,583,509,000. For the three months ended September 30, 2026, revenue was $410,145,000, cost of revenue was $129,842,000, gross profit was $280,303,000, operating expenses were $229,564,000, income from operations was $50,739,000, interest and other income, net, was $5,577,000, income before income taxes was $56,316,000, provision for income taxes was $14,037,000, and net income was $42,279,000. Net income per share for Q3 2026 was $1.07 basic and diluted. For the nine months ended September 30, 2026, revenue was $1,174,949,000, cost of revenue was $376,291,000, gross profit was $798,658,000, operating expenses were $668,646,000, income from operations was $130,012,000, interest and other income, net, was $14,179,000, income before income taxes was $144,191,000, provision for income taxes was $34,517,000, and net income was $109,674,000. Net income per share for the nine months ended September 30, 2026, was $2.79 basic and $2.77 diluted. U.S. revenue for Q3 2026 was $324,248,000, and international revenue was $85,897,000. For the nine months ended September 30, 2026, U.S. revenue was $926,080,000, and international revenue was $248,869,000. Thrombectomy revenue for Q3 2026 was $279,157,000, and embolization and access revenue was $130,988,000. For the nine months ended September 30, 2026, thrombectomy revenue was $792,055,000, and embolization and access revenue was $382,894,000.

Disagree with this article?